GeoVax Labs, Inc. (GOVX)

Market Cap	44.19M +155.9%
Revenue (ttm)	3.35M +8.5%
Net Income	-25.31M
EPS	-40.74
Shares Out	30.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,720
Open	1.470
Previous Close	1.430
Day's Range	1.320 - 1.500
52-Week Range	1.260 - 35.250
Beta	3.88
Analysts	Buy
Price Target	200.00 (+13,505.44%)
Earnings Date	Apr 30, 2026

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vacc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: GOVX
• Website: https://www.geovax.com

Analyst Summary

According to 2 analysts, the average rating for GOVX stock is "Buy." The 12-month stock price target is $200.0, which is an increase of 13,505.44% from the latest price.

Price Target

$200.0

(13,505.44% upside)

Analyst Consensus: Buy